Congestive heart failure and subclinical left ventricular systolic dysfunction (LVSD) affect long-term survivors of hematopoietic stem cell transplant (HSCT). Echocardiographic measurements of global longitudinal and circumferential strain have shown promise in identifying subclinical LVSD in cancer survivors. We analyzed echocardiograms in 95 children and young adults with malignancies or bone marrow failure syndromes performed before HSCT and 1-6 years after HSCT. We additionally measured the biomarkers soluble suppression of tumorigenicity-2 (sST-2) and cardiac troponin-I (cTn-I) in the same children through 49 days post HSCT. Ejection fraction (EF) after HSCT was unchanged from baseline (baseline: z-score − 0.73 vs long-term follow up: − 0.44, P = 0.11). Global longitudinal strain was unchanged from baseline (−20.66 vs − 20.74%, P = 0.90) as was global circumferential strain (−24.3 vs − 23.5%, P = 0.32). Levels of sST-2 were elevated at all time points compared with baseline samples and cTn-I was elevated at days 14 and 28. Cardiac biomarkers at any time point did not correlate with long-term follow-up EF. In children and young adult survivors of HSCT, EF was unchanged in the first years after HSCT. Elevation in cardiac biomarkers occurring after HSCT suggest subclinical cardiac injury occurs in many patients and long-term monitoring for LVSD should continue.
INTRODUCTION
Hematopoietic stem cell transplantation (HSCT) is a potentially curative treatment for many refractory malignancies, bone marrow failure syndromes and primary immune deficiencies in children and young adults. Cardiac injury occurs frequently in the peri-HSCT period. [1] [2] [3] [4] Left ventricular systolic dysfunction (LVSD), as measured by shortening fraction (SF) and/or ejection fraction (EF), has been described in both adult and pediatric patients undergoing HSCT. 1, [5] [6] [7] [8] [9] [10] Long-term survivors of pediatric HSCT have rates of LVSD between 0 and 26%, with the wide range due in part to non-standardized monitoring intervals, variable definitions of LVSD and differing risk factors among populations studied (for example, percent of patients who received pre-HSCT anthracyclines). 5, 11, 12 Although SF and EF are commonly used in assessing for LVSD, they are often late measures of dysfunction and do not necessarily capture myocardial injury or stress. Speckle-tracking echocardiography is a means of tracking movement patterns to determine tissue motion and deformation, and the degree of tissue deformation can then be quantified as a measure of strain in variable planes: circumferential, longitudinal and radial. A large systemic review of long-term cancer survivors showed that strain may be abnormal despite normal EF. 13 In addition, measures of strain can predict future reductions in EF or SF in adults with breast cancer, 14, 15 although these results have not replicated in children with leukemia. 16 Cardiac biomarkers are another promising approach to identify patients at risk for LVSD during HSCT. 17 Elevations in cardiac troponin in children receiving anthracycline chemotherapy have correlated with echocardiographic abnormalities four years after treatment. 18 In adults treated with trastuzumab for breast cancer, troponin elevations during treatment correlated with poor cardiac outcomes. 19 Likewise, soluble suppressor of tumorigenicity 2 (sST-2) has been shown to be an accurate measure of cardiac strain and injury outside of, [20] [21] [22] but not in the oncology setting. 15 N-terminal prohormone of brain natriuretic peptide (NT-proBNP) increases in adults undergoing HSCT but has not been tied to later cardiac effects in small samples. 23 In an effort to increase our ability to identify LVSD after HSCT, we examined standard echocardiographic measurements and myocardial strain parameters in patients at baseline and at long-term follow-up (LTFU). In addition, we measured the serum biomarkers sST-2, NT-proBNP and cardiac troponin-I (cTn-I) around the time of HSCT to determine whether levels could predict LVSD in long-term survivors
PATIENTS AND METHODS
Patients who underwent HSCT for either malignancy or bone marrow failure syndrome at Cincinnati Children's Hospital Medical Center between 2011 and 2015, and were alive 1 year after HSCT, were enrolled in the study. Eligible patients had an echocardiogram within 30 days before HSCT and at least one echocardiogram performed ⩾ 1 year after HSCT, and must have consented to specimen collection for the Cincinnati Children's HSCT repository (~85% of patients consent). We obtained Institutional Review Board approval for this study.
A pediatric cardiologist reviewed all echocardiograms and compared echocardiographic parameters at baseline and LTFU, taken as the most recent echocardiogram performed greater ⩾ 1 year after HSCT. Additional measurements of myocardial strain were performed if echocardiographic windows were appropriate. Biomarkers from the peri-HSCT period were assayed from plasma stored in the HSCT repository and clinical variables were obtained from the electronic medical record. Echocardiographic criteria were then compared with biomarkers and clinical factors.
Data collection
We collected data, including graft source, diagnosis, preparative regimen (including chemotherapy and total body irradiation), previous anthracycline exposure and cumulative anthracycline dose, alemtuzumab use (both for conditioning and acute GvHD treatment), viremia (positivity for plasma adenovirus, EBV, or CMV detectable by polymerase chain reaction), bacteremia (defined as a positive blood culture in the first 100 days after HSCT, clinical diagnosis of transplant associated-thrombotic microangiopathy 24 and acute GvHD. 25, 26 We obtained PCR testing for adenovirus, EBV and CMV weekly for all patients as part of standard clinical care.
Echocardiograms
All echocardiograms were performed on the iE33 ultrasound system (Phillips Medical Systems, Best, The Netherlands). Dimensions measured were converted to age adjusted z-scores using the Boston Children's Hospital z-score system. 27 , Values were considered abnormal if they fell more than two z-scores below the mean (zero). We calculated EF using Simpson's method, if this was not available on report, a cardiologist blinded to the study calculated EF using the 5/6 Area-Length method. Offline calculations of global longitudinal strain (GLS) and global circumferential stain (GCS) were performed using vendor-independent clinical echocardiographic software (Image Arena, TomTec Imaging Systems, Munich, Germany). Normal values for strain have not been definitively set across the various available echocardiogram platforms and analysis software. Based on recent guideline recommendations and a meta-analysis, conservative values were chosen for the present analysis that may underestimate the amount of dysfunction. We considered GLS abnormal if values were 4 − 16% and GCS abnormal if values were 4 − 18%. 28, 29 Biomarker testing Plasma samples prospectively collected during the peri-HSCT period were stored at − 80°C from patients consented to the repository. cTn-I, sST-2 and NT-proBNP were measured at baseline, during conditioning and at days +7, +14, +28 and +49 after transplant. We evaluated serum cTn-I using a CLIA-certified Luminescent Oxygen Channeling Immunoassay. We evaluated plasma sST2 using ELISA (R&D Systems, Minneapolis, MN, USA, catalog number DST200, samples run in duplicate) and NT-proBNP using ELISA (Ray Biotech, Norcross, GA, USA, catalog number ELH-proBNP-1, samples run in duplicate).
Statistical analysis
Data were exported to GraphPad Prism (La Jolla, CA, USA) for analysis. An independent two-sample t-test was used to calculate two-tailed P-values between normally distributed groups and Wilcoxon rank-sum test was used for non-parametric data. Categorical variables were tested using a two-tailed Fisher's exact test. We used McNemar's test to assess correlation between paired nominal data. We calculated Spearman's rank correlation coefficient to assess the relationship between biomarkers and EF at LTFU, and we used a Bonferroni correction to allow for multiple comparisons.
RESULTS

Patient demographics
Between 2011 and 2015, 95 patients underwent HSCT for malignancy or bone marrow failure syndrome, were alive at 1 year after HSCT, consented to the HSCT repository and had echocardiograms obtained (Table 1) . Thirteen patients who were transplanted during this timeframe and met other inclusion criteria did not have echocardiograms performed. The mean time from most recent LTFU echocardiogram to time of HSCT was 2.3 years (range: 1.0-5.6 years). Notably, 46.3% of patients had previous anthracycline exposure (mean 192 mg/m 2 ) and 22.1% had total body irradiation as part of HSCT conditioning regimen.
Echocardiographic changes A small minority of echocardiograms were performed at outside institutions (5/95 at baseline and 6/95 at LTFU) and did not contain measures of SF, EF or strain. SF after HSCT was slightly decreased from baseline (z-score 0.21 vs − 0.09, P = 0.06) but still in the normal range (Figure 1 ). EF after HSCT was unchanged from baseline (z-score − 0.73 vs − 0.44, P = 0.11). Left ventricular end diastolic dimension decreased after HSCT (z-score 0.04 vs − 0.81, Po 0.0001) and septal thickness increased after HSCT (z-score − 1.27 vs − 0.92, P o 0.01). We observed no significant difference for posterior wall thickness (z-score − 1.09 vs − 1.10, P = 0.98). Abbreviations: aGvHD = aGvHD: acute GvHD; HSCT = hematopoietic stem cell transplant; TA-TMA = transplant associated-thrombotic microangiopathy; TBI = total body irradiation. Long-term systolic function
We additionally compared EF and SF at baseline and LTFU looking at the non-age adjusted data (Supplementary Figure 1) . The mean (range) EF at baseline and LTFU was 60.2% (46.0-73.5%) vs 61.6% (43.0-76.9%), (P = 0.06). The mean (range) SF at baseline and LTFU was 36.7% (28.1-48.0%) vs 35.1% (24.0-48.4%), (P = 0.01).
We compared patients with abnormal measurements (o 2 s.d. below the age adjusted mean) before and after transplant. Three of 91 had abnormal SF pre-HSCT vs 6/92 (one of six of these patients was abnormal at baseline and five of these six patients were normal at baseline) at LTFU (P = 0.44) and 5/91 had abnormal EF pre-HSCT vs 2/93 (both normal at baseline) at LTFU (P = 0.68). In addition, 7/91 had abnormal left ventricular end diastolic dimension pre-HSCT vs 16/95 (one abnormal at baseline) at LTFU (P = 0.10) and 14/91 (7 abnormal at baseline) had abnormal left ventricular free wall thickness pre-HSCT vs 19/95 (3 abnormal at baseline) at LTFU (P = 0.55). As well, 22/92 had abnormal left ventricular septal thickness pre-HSCT vs 13/95 at LTFU (P = 0.04).
Measurements of strain GLS was unchanged from baseline (−20.66 vs − 20.74%, P = 0.90) as was GCS (−24.3 vs − 23.5%, P = 0.32) (Figure 2 ). Before HSCT, 10/86 patients had GLS4 − 16% compared with 5/75 patients at LTFU (P = 0.75). Before HSCT, 6/84 patients had GCS4 − 18% compared with 10/76 patients at LTFU (P = 0.61).
Biomarkers
The mean baseline plasma cTn-I level for all specimens at baseline was 0.024 ng/mL (normal o 0.015 ng/mL). Mean levels rose until day +14 before trailing off, and were significantly elevated compared to baseline at days +14 and +28 (Figure 3a) . The mean baseline plasma sST-2 level for all specimens at baseline was 24.4 ng/mL (normal o 6.3 ng/mL). Mean levels rose until day +14 before trailing off, and were significantly elevated compared with baseline at all time points (Figure 3b ). The mean baseline plasma NT-proBNP level for all specimens at baseline was 785.9 pg/mL (normal o 150 pg/mL). Mean levels rose until day +7 before trailing off and were significantly elevated compared with baseline during conditioning regimen, day +7 and day +14 (Figure 3) . Serum biomarkers and clinical data to predict EF at LTFU We calculated a Spearman's rank correlation coefficient using cTn-I, sST-2 and NT-proBNP at each time point versus EF at LTFU. Day +7 cTn-I was negatively correlated with EF at LTFU (r = − 0.25, P = 0.02), but this failed to reach statistical significance after a Bonferroni correction. No other biomarkers at any time points were associated with EF at LTFU. No significant differences in EF, SF, GLS, or GCS at LTFU were seen in patients who did or did not receive pre HSCT anthracyclines, conditioning agents such as TBI, Cyclophosphamide or alemtuzumab or in patients who did or did not experience GvHD or transplant associated-thrombotic microangiopathy. In addition, pre-HSCT GLS and GCS were not associated with EF or SF after HSCT. 
DISCUSSION
This study highlights the encouraging finding that most children and young adults will not develop measurable systolic dysfunction in the first few years after HSCT, despite evidence for myocardial stress and injury during therapy. Measurements of EF and SF were not significantly different from baseline before HSCT at a mean of 2.3 years after HSCT. We hypothesized that GLS and GCS might detect LVSD when EF and SF are normal, but found that these measures also did not change between baseline and LTFU. Previous studies in adults have shown that cardiac risk due to pre-HSCT therapies and/or HSCT itself are magnified when combined with other adult-onset risk factors. In particular, risk factors for cardiac disease in non-transplanted adults such as diabetes mellitus, hypertension, [30] [31] [32] dyslipidemia, 33 ischemic heart disease 30 and chronic kidney disease 32 have also been strongly associated with heart failure in adults after HSCT. Long-term HSCT survivors have a high prevalence of metabolic syndrome 34 and allogeneic HSCT is associated with premature cardiovascular disease. 35 One explanation for the lack of change in systolic function in this study is that the observed patients (mean age at follow up 12.4 years) have not had time to develop additional cardiac risk factors, so we will continue to screen this cohort of patients aggressively.
Despite the lack of change in systolic function for the cohort overall, a minority of long-term survivors of HSCT in this study did have systolic dysfunction. Aggressive medical treatment of patients with LVSD on echocardiogram, even if asymptomatic, is likely to be beneficial. 36 Adults receiving anthracycline therapy with echocardiographic abnormalities who are diagnosed and started on therapy earlier are more likely to respond to conventional heart failure interventions. 37 It is currently unknown whether this benefit also occurs after HSCT in patients without anthracycline exposure. β-Blockers and angiotensin-converting enzyme inhibitors have shown efficacy in the setting of anthracycline-induced cardiac dysfunction. 38 Their use may prevent reductions in EF in adults undergoing treatment for hematologic malignancies. 39 In addition, angiotensin-converting enzyme inhibitors were beneficial in preventing reduction in EF in adults undergoing autologous HSCT when patients were risk stratified by troponin levels monitored during therapy. 40 As our data displayed elevated troponin from baseline during therapy, further studies of these agents in children in the peri-HSCT period are warranted.
One notable change that occurred during the study period was a decrease in left ventricular end diastolic dimension, together with an increase in septal thickness, while left ventricular free wall thickness remained unchanged. An explanation for these phenomena may be that patients had a relative dilation of the left ventricle prior to transplant from chronic anemia related to malignancy or bone marrow failure. Transplantation would presumably lead to normalization of hemoglobin mass in patients, and one would expect a normalization of ventricular dilatation in these patients.
Although multiple cardiac biomarkers did not predict changes in systolic function in our population, all biomarkers increased from baseline during HSCT. An apparent association in this study between day +7 cTn-I and EF at LTFU, although not statistically significant after adjustment for multiple comparisons, should be evaluated further. Elevated levels of cardiac biomarkers are indicative of myocardial stress or damage. The effects of cardiotoxic therapies may be too modest to be detected by echocardiography in the first few years after HSCT, and only become evident once significant cardiac reserves are depleted. 41 Our study has several limitations. First, the mean follow-up period in our patients was 2.3 years. Although this may be enough time for echocardiographic changes to occur in patients with severe cardiomyopathy, it may not reflect a long enough time period in patients with more modest injury. Second, our study is limited by the number of patients we followed (n = 95). A larger study with similar scope might allow for the recognition of correlation between biomarkers and long-term systolic dysfunction. Similarly, this study was limited to patients with malignancies or bone marrow failure syndromes, and patients with other diagnoses (that is, hemoglobinopathies and primary immune deficiencies) may have additional risk factors (that is, iron overload), which warrant long-term cardiac risk consideration. A recent study showed that children who underwent autologous transplant had subtle changes in diastolic parameters of echocardiogram 3 months post transplant. 42 We did not routinely perform tissue Doppler imaging, which is necessary to detect abnormalities in diastolic functioning, and may be revealing to review in an additional cohort of patients. In addition, levels of biomarkers were assayed every 1-3 weeks during HSCT. Although this strategy might pick up more substantial cardiac injury (sST-2 and cTn-I) or ongoing ventricular strain (NT-proBNP), it is possible that this approach did not provide enough granularity to detect clinically relevant injuries. In addition, we did not measure biomarkers after day +49 and events occurring after this time frame may contribute to late LVSD. Biomarkers may also be reflective of other events occurring in the peri-HSCT period, such as sST2, which is associated with both GvHD and transplant associated-thrombotic microangiopathy. 43, 44 Finally, we did not routinely collect data on after HSCT cardiac risk factors such as hyperlipidemia, insulin resistance, hypertension and smoking status, although these issues would be expected to be much less frequent than in adults after HSCT.
In summary, in children and young adult survivors of HSCT, systolic function was preserved 2.3 years after HSCT. Elevation in cardiac biomarkers occurring after HSCT suggest subclinical cardiac injury occurs in many patients undergoing HSCT, and long term monitoring for LVSD should continue. [45] [46] [47] 
